Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Cash & Equivalents (2020 - 2025)

iSpecimen has reported Cash & Equivalents over the past 6 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $6.9 million for Q4 2025, up 266.31% from a year ago — trailing twelve months through Dec 2025 was $6.9 million (up 266.31% YoY), and the annual figure for FY2025 was $6.9 million, up 266.31%.
  • Cash & Equivalents for Q4 2025 was $6.9 million at iSpecimen, up from $2.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ISPC hit a ceiling of $27.7 million in Q4 2021 and a floor of $588775.0 in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $2.8 million (2025), compared with a mean of $8.7 million.
  • Biggest five-year swings in Cash & Equivalents: surged 3886.01% in 2021 and later tumbled 91.54% in 2023.
  • iSpecimen's Cash & Equivalents stood at $27.7 million in 2021, then crashed by 44.81% to $15.3 million in 2022, then crashed by 84.69% to $2.3 million in 2023, then fell by 19.85% to $1.9 million in 2024, then soared by 266.31% to $6.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $6.9 million (Q4 2025), $2.8 million (Q3 2025), and $588775.0 (Q2 2025) per Business Quant data.